logo
Twitter
Discord
Email
logo
Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc.

NASDAQ•DNTH
CEO: Mr. Marino Garcia M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2018-06-21
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Contact Information
7 Times Square, 43rd Floor, New York, NY, 10036, United States
929-999-4055
dianthustx.com
Market Cap
$1.13B
P/E (TTM)
-10.9
17.1
Dividend Yield
--
52W High
$40.16
52W Low
$13.37
52W Range
81%
2.3
F-Score
Modified Piotroski Analysis
Based on 9-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2024

Financial Dashboard

Q2 2025 Data

Revenue

$193.00K-89.64%
4-Quarter Trend

EPS

-$0.88+72.55%
4-Quarter Trend

FCF

-$23.94M+64.58%
4-Quarter Trend

2025 Q2 Earnings Highlights

Key Highlights

Extended Cash Runway Secured Cash, cash equivalents, and investments totaled 309.1M USD as of June 30, 2025, funding operations into the second half of 2027.
R&D Investment Accelerates Clinical Trials Research and development expenses surged 22.1M USD to 53.3M USD in H1 2025, supporting ongoing Phase 2/3 trials.
Lead Candidate Trial Enrollment Complete Phase 2 MaGic trial enrollment for lead candidate claseprubart completed May 2025; top-line results anticipated in September 2025.

Risk Factors

High Accumulated Deficit Accumulated deficit reached 235.5M USD as of June 30, 2025, reflecting significant recurring losses since company inception.
Clinical Trial Success Uncertainty Successful development of lead candidate claseprubart is highly uncertain, requiring significant capital and regulatory approval efforts.
Future Capital Requirements High Substantial additional capital needed for development and commercialization; failure to secure funding risks trial delay or termination.

Outlook

CIDP and MMN Data Expected Anticipate initial top-line results for Phase 2 MMN trial and Phase 3 CIDP interim analysis in the second half of 2026.
Operating Expenses Expected to Rise R&D and G&A costs will increase significantly to support advancing claseprubart into larger clinical trials and commercialization activities.
Maintain ATM Offering Capacity Company retains 160.8M USD remaining capacity under the At-The-Market offering program for potential future equity financing.

Peer Comparison

Revenue (TTM)

Wave Life Sciences Ltd.WVE
$93.95M
-15.0%
Nektar TherapeuticsNKTR
$74.93M
-19.6%
Nuvation Bio Inc.NUVB
$14.36M
+744.9%

Gross Margin (Latest Quarter)

Nektar TherapeuticsNKTR
98.1%
+39.6 pp
Taysha Gene Therapies, Inc.TSHA
86.1%
-13.9 pp
Wave Life Sciences Ltd.WVE
74.8%
-25.2 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
PRAX$4.18B-17.0-60.1%0.2%
NUVB$1.79B-8.8-46.1%31.4%
WVE$1.44B-11.4-74.9%8.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-55.4%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Reports
All Years

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $193.00K-89.6%
    |
    EPS: $-0.88+72.5%
    Meet

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 12, 2025|
    Revenue: $1.16M+33.1%
    |
    EPS: $-0.82+51.9%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 11, 2025|
    Revenue: $6.24M+120.6%
    |
    EPS: $-2.55+69.8%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $2.17M+135.1%
    |
    EPS: $-0.74-80.4%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $1.86M+92.3%
    |
    EPS: $-0.51-41.4%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 9, 2024|
    Revenue: $874.00K+83.6%
    |
    EPS: $-0.54-93.0%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 21, 2024|
    Revenue: $2.83M-56.0%
    |
    EPS: $-8.45-11.2%
    Miss

  • Form 10-Q - Q3 2023

    Period End: Sep 30, 2023|Filed: Nov 9, 2023|
    Revenue: $924.00K-21.2%
    |
    EPS: $-3.78+80.0%
    Miss